|
May 15
|
Profound Medical Annual General Meeting of Shareholders Voting Results
|
|
May 14
|
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
|
|
May 11
|
Profound Medical First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 9
|
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
|
|
May 6
|
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
|
|
May 3
|
In the wake of Profound Medical Corp.'s (TSE:PRN) latest CA$31m market cap drop, institutional owners may be forced to take severe actions
|
|
Apr 22
|
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
|
|
Apr 9
|
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
|
|
Apr 6
|
Shareholders in Profound Medical (TSE:PRN) are in the red if they invested three years ago
|
|
Mar 10
|
Profound Medical Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 7
|
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 4
|
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
|
|
Jan 16
|
Profound Medical Announces Non-Brokered Private Placement
|
|
Dec 28
|
Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares
|
|
Dec 27
|
Profound Medical Announces Proposed Public Offering of Common Shares
|